首頁 > 市場調查報告書 > 製藥

處方藥

市場調查報告書

商品編碼

1983217

代謝藥物市場：按治療方法、應用、分銷管道和地區分類

Metabolism Drugs Market, By Therapy Type, By Application, By Distribution Channel, By Geography

出版日期: 2026年02月12日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年代謝藥物市場規模估計為148億美元，預計2033年將達到182.1億美元。預計2026年至2033年，該市場將以8.1%的複合年成長率成長。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	148億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2026-2033 年）複合年成長率	8.10%	預計金額（2033 年）	182.1億美元

當體內無法產生酵素或蛋白質（遺傳性疾病），或產生的酵素無法發揮其應有的功能時，代謝功能就會停止正常運作。代謝紊亂是由於蛋白質、脂質、肝醣、尿素、鈣結石和毒性物質的累積所造成的。每種分子都有其特定的代謝途徑和代謝因子（酵素、蛋白質）在其中發揮作用。當這些因子無法正常發揮作用時，這些分子就會在血液和身體其他部位累積。代謝紊亂的例子包括高雪氏症、遺傳性酪胺酸血症、遺傳性乳清酸尿症和法布瑞氏症。

市場動態

預計在預測期內，非內生性成長活動（例如市場參與者之間的合作與協議）的增加將推動市場成長。例如，2021年12月10日，製藥公司禮來公司（Eli Lilly and Company）和生物技術公司Regor Therapeutics Group宣布了一項多年研究合作及許可協議，旨在發現、開發和商業化用於治療代謝疾病的新治療方法。根據該協議，禮來公司將選擇性地獲得Regor部分智慧財產權的許可，並可選擇延長許可期限。禮來公司將負責除中國大陸、澳門、香港和台灣地區以外的全球範圍內的臨床開發、生產和商業化。

此外，市場相關人員越來越關注酵素替代療法的臨床試驗。例如，2020年6月16日，全球生物製藥公司賽諾菲宣布，基於一項3期臨床試驗的結果，其在臨床實驗酶替代療法（ERT）Glucosidaseα在改善晚髮型龐貝病（LOPD）的主要症狀（即呼吸功能障礙和運動功能減退）方面顯示出顯著的臨床療效。Glucosidaseα在改善LOPD患者的呼吸功能方面，療效不劣於Glucosidaseα（標準治療），達到了其主要終點。

本報告的主要特點

本報告對全球代謝藥物市場進行了詳細分析，包括預測期（2026-2033 年）的市場規模和複合年成長率，以 2025 年為基準年。
此外，它還確定了每個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本節根據以下參數介紹全球代謝藥物市場主要企業的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
《全球代謝藥物市場》報告面向該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過分析全球代謝藥物市場中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第8章競爭情勢

熱圖分析
市佔率分析（3x3矩陣）
公司簡介
- Merck &Co., Inc.
- Novartis AG
- Amicus Therapeutics
- AstraZeneca Plc
- Boehringer Ingelheim
- Shire Plc
- Sanofi Genzyme
- BioMarin Pharmaceutical, Inc.
- Horizon Pharma Plc.
- GlaxoSmithKline Plc.

第9章分析師建議

機會
分析師意見
Coherent Opportunity Map (COM)

第10章：參考文獻與分析方法

參考
分析方法

簡介目錄

Product Code: CMI1955

Metabolism Drugs Market is estimated to be valued at USD 14.8 Bn in 2026 and is expected to reach USD 18.21 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 14.8 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	8.10%	2033 Value Projection:	USD 18.21 Bn

Metabolism functions improperly when enzymes and proteins are either not produced by the body (inherited disorders), or the produced enzymes do not function the way they are meant to. Metabolic disorders occur due to buildup of proteins, lipids, glycogen, urea, calcium stones, and toxic substances among others. Each of these molecules have certain designated metabolic pathways, and metabolic agents (enzymes, proteins) at work. Inability of these agents to carry out their tasks cause buildup of the molecules in the blood and other places. Few examples of metabolic diseases include gaucher disease, hereditary tyrosinemia, hereditary orotic aciduria, and fabry disease.

Market Dynamics

Increasing inorganic growth activities such as collaborations and agreement among market players is expected to drive the market growth over the forecast period. For instance, on December 10, 2021, Eli Lilly and Company, a pharmaceutical company and Regor Therapeutics Group, a biotechnology company announced multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders. According to this agreement, Eli Lilly will have a license to select Regor intellectual property with an option to extend the license. Lilly will be responsible for clinical development, manufacturing and commercialization worldwide, except for People's Republic of China, Macau, Hong Kong and Taiwan.

Furthermore, market players are increasingly focusing on clinical trials for development of enzyme replacement therapy. For instance, on June 16, 2020, Sanofi, a global biopharmaceutical company announced the results for investigational enzyme replacement therapy (ERT), avalglucosidase alfa that showed clinically meaningful improvement in critical manifestations (respiratory impairment and decreased mobility) of late-onset Pompe disease (LOPD), according to results from the Phase 3 trial. Avalglucosidase alfa met the primary endpoint demonstrating non-inferiority in improving respiratory function compared to alglucosidase alfa (standard of care) in patients with LOPD.

Key features of the study

This report provides an in-depth analysis of the global metabolism drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global metabolism drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global metabolism drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global metabolism drugs market

Market Segmentation

By Therapy Type
- Enzyme Replacement Therapy
- Substrate Reduction Therapy
- Small Molecule Drugs
- Others
By Application
- Glycogen Metabolism Disease
- Lipid Metabolism Disease
- Amino Acid Metabolism Disease
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Merck & Co., Inc.
- Novartis AG
- Amicus Therapeutics
- AstraZeneca Plc
- Boehringer Ingelheim
- Shire Plc
- Sanofi Genzyme
- BioMarin Pharmaceutical, Inc.
- Horizon Pharma Plc
- GlaxoSmithKline Plc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- PEST Analysis
- PORTER's Five Forces Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend

4. Global Metabolism Drugs Market, By Therapy Type, 2026-2033, (USD Bn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Enzyme Replacement Therapy
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Substrate Reduction Therapy
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Small Molecule Drugs
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

5. Global Metabolism Drugs Market, By Application, 2026-2033, (USD Bn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Glycogen Metabolism Disease
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Lipid Metabolism Disease
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Amino Acid Metabolism Disease
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

6. Global Metabolism Drugs Market, By Distribution Channel, 2026-2033, (USD Bn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Retail Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Online Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

7. Global Metabolism Drugs Market, By Region, 2026-2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - U.S.
  - Canada
Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis (3x3 Matrix)
Company Profiles
- Merck & Co., Inc.
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Novartis AG
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Amicus Therapeutics
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- AstraZeneca Plc
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Boehringer Ingelheim
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Shire Plc
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Sanofi Genzyme
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- BioMarin Pharmaceutical, Inc.
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Horizon Pharma Plc.
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- GlaxoSmithKline Plc.
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates